# A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

> **NCT07169734** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alentis Therapeutics AG** · enrollment: 180 (estimated)

## Conditions studied

- Cervical Squamous Cell Carcinoma
- Squamous Non-small-cell Lung Cancer
- Colorectal Cancer
- Intrahepatic Cholangiocarcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** ALE.P03
- **DRUG:** ALE.P03
- **DRUG:** ALE.P03

## Key facts

- **NCT ID:** NCT07169734
- **Lead sponsor:** Alentis Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-26
- **Primary completion:** 2029-04-05
- **Final completion:** 2029-10-04
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169734, "A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07169734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*